Effects of Highly Active Antiretroviral Therapy on Platelet Activating Factor Metabolism in Naïve HIV-Infected Patients: II) Study of the Abacavir/Lamivudine/Efavirenz Haart Regimen

Abstract

Human Immunodeficiency Virus (HIV)-infected patients are at increased risk for cardiovascular diseases partly due to chronic inflammation. Some antiretroviral drugs and Highly Active Anti-Retroviral Therapy (HAART) regimens seem to be related and amplify this increased risk, especially the ones containing abacavir. Platelet-Activating-Factor (PAF) is a potent inflammatory mediator that is implicated in both cardiovascular diseases and HIV-related manifestations. Our objective is to study the in vivo effect of the abacavir/lamivudine/efavirenz first-line HAART regimen on PAF metabolism in HIV-infected patients. The specific activities of PAF basic biosynthetic enzymes in leukocytes and platelets, PAF-cholinephosphotransferase (PAF-CPT) and lyso-PAF-acetyltransferase (Lyso-PAF-AT), but also those of PAF-basic catabolic enzymes, PAF acetylhydrolase (PAF-AH) in leukocytes and platelets and Lipoprotein-associated-Phospholipase-A₂ (LpPLA₂) in plasma, were measured in blood samples of 10 asymptomatic naïve male HIV-infected patients just before and after 1, 3 and 6 months of treatment. CD4 cell counts, viral load and several biochemical markers were also measured in the same blood samples of these patients. The repeated ANOVA measures and the Pearson r criterion were used for studying statistical differences and correlations - partial correlations respectively. Even though viral load was decreased and CD4 cell counts were beneficially increased after treatment with the abacavir/lamivudine/efavirenz regimen, the main enzyme of the remodelling PAF-synthesis that is implicated in pro-atherogenic inflammatory procedures, Lyso-PAF-AT activity, was increased at 3 months of treatment in both leukocytes and platelets, while the main enzyme of PAF-degradation, PAF-AH, was increased as a response only in leukocytes at the 3^rd month. Although the abacavir/lamivudine/efavirenz HAART regimen exhibits very efficient antiretroviral activities, on the other hand it induces an in vivo transient increase in the inflammation-related remodeling PAF-biosynthetic pathway. This finding supports the hypothesis of inflammation-mediated increased cardiovascular risk in HIV-infected patients during the first months of abacavir-containing HAART.

Keywords

Human Immunodeficiency Virus (HIV)Highly Active Anti-Retroviral Therapy (HAART)abacavir Platelet Activating Factor (PAF)Inflammation Cardiovascular Disease (CVD)

References

Demopoulos

Pinckard

Hanahan

. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem 1979; 254:9355–8.

Stafforini

McIntyre

Zimmerman

Prescott

. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Cl Lab Sci 2003; 40:643–72.

Zimmerman

McIntyre

Prescott

Stafforini

. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002; 30:S294–301.

Montrucchio

Alloatti

Camussi

. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev 2000; 80:1669–99.

Demopoulos

Karantonis

Antonopoulou

. Platelet activating factor - a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol 2003; 105:705–16.

Nomikos

Fragopoulou

Antonopoulou

. Food ingredients and lipid mediators. Curr Nutr Food Sci 2007; 3:255–76.

Tsoupras

Iatrou

Frangia

Demopoulos

. The implication of platelet activating factor in cancer growth and metastasis: Potent beneficial role of PAF-inhibitors and antioxidants. Infect Disord Drug Targets 2009; 9:390–9.

Gimenez

Aguilar

. Cytidine (5-) diphosphocholine induced decrease in cerebral platelet activating factor is due to inactivation of its synthesizing enzyme cholinephosphotransferase in aged rats. Neurosci Lett 2001; 299:209–12.

Tsoupras

Chini

Tsogas

. Platelet activating factor basic metabolic enzymes in blood of naive HIV-infected patients. Angiology 2011; Epub ahead of print.

10.

Shindou

Hishikawa

Nakanishi

. A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acetyl-CoA:LYSO-PAF acetyltransferase. J Biol Chem 2007; 282:6532–9.

11.

Antonopoulou

Demopoulos

Iatrou

Moustakas

Zirogiannis

. Platelet-activating factor acetylhydrolase (PAF-AH) in human kidney. Int J Biochem 1994; 26:1157–62.

12.

Doublier

Zennaro

Spatola

. HIV-1 Tat reduces nephrin in human podocytes: A potential mechanism for enhanced glomerular permeability in HIV-associated nephropathy. AIDS 2007; 21:423–32.

13.

Perry

Hamilton

Tjoelker

. Platelet-activating factor receptor activation. An initiator step in HIV-1 neuropathogenesis. J Biol Chem 1998; 273: 17660–4.

14.

Biancone

Cantaluppi

Boccellino

. Motility induced by human immunodeficiency virus-1 Tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis. Am J Pathol 1999; 155: 1731–9.

15.

Meltzer

Skillman

Gomatos

Kalter

Gendelman

. Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection. Annu Rev Immunol 1990; 8:169–94.

16.

Genis

Jett

Bernton

. Cytokine and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: Implications for the neuropathogenesis of HIV disease. J Exp Med 1992;176:1703–18.

17.

Lima

Moreira

Paes-Leme

. Interaction of macrophages with apoptotic cells enhances HIV Type 1 replication through PGE2, PAF, and vitronectin receptor. AIDS Res Hum Retroviruses 2006; 22:763–9.

18.

Currier

. Update on cardiovascular complications in HIV infection. Top HIV Med 2009; 17:98–103.

19.

Malvestutto

Aberg

. Coronary heart disease in people infected with HIV. Cleve Clin J Med 2010; 77:547–56.

20.

Tsoupras

Chini

Tsogas

. Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): A new insight in the drug therapy of HIV infection? AIDS Res Hum Retroviruses 2008;24:1079–86.

21.

Chini

Tsoupras

Mangafas

. Effects of HAART on Platelet Activating Factor metabolism in naive HIV-infected patients I; Study of the tenofovir-DF/emtricitabine/efavirenz HAART regimen. AIDS Res Hum Retroviruses 2011; Epub ahead of print.

22.

Behrens

Reiss

. Abacavir and cardiovascular risk. Curr Opin Infect Dis 2010; 23:9–14.

23.

Tsoupras

Chini

Tsogas

Mangafas

Demopoulos

Lazanas

. In vivo effects of a Ginkgo biloba extract on platelet activating factor metabolism in two asymptomatic HIV-infected patients. Eur J Inflamm 2011; 9:107–16.

24.

Bradford

. A rapid and sensitive method for the quantization of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248–54.

25.

Bligh

Dyer

. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959;37:911–7.

26.

Lundgren

Neuhaus

Babiker

. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22: F17–24

27.

Martin

Amin

Cooper

. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: A randomized clinical trial. AIDS 2010; 24:2657–63.

28.

Bernatchez

Winstead

Dennis

Sirois

. VEGF stimulation of endothelial cell PAF synthesis is mediated by group V 14 κDa secretory phospholipase A2. Br J Pharmacol 2001; 134:197–205.

29.

Dulioust

Vivier

Salem

Benveniste

Thomas

. Immunoregulatory functions of paf-acether. I. Effect of paf-acether on CD4+ cell proliferation. J Immunol 1988; 140:240–5.

30.

Khovidhunkit

Memon

Shigenaga

. Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism 1999;48:1524–31.